United States - English - NLM (National Library of Medicine)

hospira, inc. - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection usp (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection usp (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. mitoxantrone injection usp (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 10 mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 20 mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 30 mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

toxant insecticide manufacturing co - piperonyl butoxide | pyrethrin - household insecticide - domestic and/or public area - flying insect | flies | mosquitoes | moths